



ABN 53 075 582 740

ASX ANNOUNCEMENT
31 August 2012

BNC210 partner Ironwood Pharmaceuticals receives US FDA approval for LINZESS™

31 August 2012: Bionomics Limited (ASX:BNO, ADR: BMICY) BNC210 partner Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) achieved a major milestone overnight by gaining US FDA approval for linaclotide. The drug, to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), will be sold under the brand name LINZESS™.

Ironwood and partner Forest Laboratories expect to commence marketing later this year in the US.

Ironwood will receive a US\$85 million payment from Forest Laboratories in recognition of this milestone achievement.

To view a copy of the announcement, insert the following details into your web browser:
ironwoodpharma.com/newsPDF/08.30.12%20LINZESS%20Approval%20FINAL.pdf

Enquiries:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101/
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, Alzheimer's disease, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.
www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a

number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNC105 or BNC210, our partnerships with Merck Serono and Ironwood Pharmaceuticals, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.